{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T10:44:11Z","timestamp":1790160251390,"version":"4.1.0"},"reference-count":29,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,2,23]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Second-generation tyrosine kinase inhibitors (2G-TKIs) are effective at inducing complete cytogenetic responses (CCyRs) in approximately half of chronic myeloid leukemia patients treated while still in the chronic phase and after failing imatinib. It is less clear whether these responses are durable. In the present study, we report the clinical outcome of 119 patients who received a 2G-TKI as second-line treatment while still in the chronic phase. In an intention-to-treat analysis, the 4-year probabilities of overall and event-free survival were 81.9% and 35.3%, respectively. Sixty-two patients discontinued the initial 2G-TKI because of resistance or intolerance. To further explore the durability of cytogenetic responses, irrespective of the need for a third-line TKI, we used the concept of \u201ccurrent CCyR-survival\u201d (c-CCyRS). The c-CCyRS at 4 years was 54.4%. After introduction of a 2G-TKI, 77 patients had a 3-month BCR-ABL1\/ABL1 transcript ratio of \u2264 10% and had significantly superior overall survival (91.3% vs 72.1%, P = .02), event-free survival (49.3% vs 13.0%, P &lt; .001), and c-CCyRS (67.2% vs 11.2%, P = .0001) compared with the 33 patients with ratios &gt; 10%. The 3-month molecular response was the only independent predictor for overall survival. Using an intention-to-treat analysis, we have shown that the responses to second-line therapies are durable. Patients destined to fare poorly can be identified early during therapy.<\/jats:p>","DOI":"10.1182\/blood-2011-10-383000","type":"journal-article","created":{"date-parts":[[2011,12,15]],"date-time":"2011-12-15T06:03:30Z","timestamp":1323929010000},"page":"1838-1843","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":53,"title":["Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients"],"prefix":"10.1182","volume":"119","author":[{"given":"Dragana","family":"Milojkovic","sequence":"first","affiliation":[{"name":"Department of Haematology, Imperial College London, Hammersmith Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane F.","family":"Apperley","sequence":"additional","affiliation":[{"name":"Department of Haematology, Imperial College London, Hammersmith Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gareth","family":"Gerrard","sequence":"additional","affiliation":[{"name":"Department of Haematology, Imperial College London, Hammersmith Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amr R.","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"Department of Haematology, Imperial College London, Hammersmith Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Szydlo","sequence":"additional","affiliation":[{"name":"Department of Haematology, Imperial College London, Hammersmith Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Bua","sequence":"additional","affiliation":[{"name":"Department of Haematology, Imperial College London, Hammersmith Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alistair","family":"Reid","sequence":"additional","affiliation":[{"name":"Department of Haematology, Imperial College London, Hammersmith Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katayoun","family":"Rezvani","sequence":"additional","affiliation":[{"name":"Department of Haematology, Imperial College London, Hammersmith Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letizia","family":"Foroni","sequence":"additional","affiliation":[{"name":"Department of Haematology, Imperial College London, Hammersmith Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Goldman","sequence":"additional","affiliation":[{"name":"Department of Haematology, Imperial College London, Hammersmith Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Marin","sequence":"additional","affiliation":[{"name":"Department of Haematology, Imperial College London, Hammersmith Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"2","key":"2019111809573930100_B1","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3324\/haematol.2009.012781","article-title":"Early prediction of success or failure using second generation tyrosine kinase inhibitors for chronic myeloid leukemia.","volume":"95","author":"Milojkovic","year":"2010","journal-title":"Haematologica"},{"issue":"24","key":"2019111809573930100_B2","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.","volume":"354","author":"Talpaz","year":"2006","journal-title":"N Engl J Med"},{"issue":"24","key":"2019111809573930100_B3","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N Engl J Med"},{"issue":"4","key":"2019111809573930100_B4","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1182\/blood-2010-03-277152","article-title":"Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results.","volume":"117","author":"Kantarjian","year":"2011","journal-title":"Blood"},{"issue":"2","key":"2019111809573930100_B5","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3324\/haematol.2009.011452","article-title":"Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib.","volume":"95","author":"Shah","year":"2010","journal-title":"Haematologica"},{"issue":"6","key":"2019111809573930100_B6","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1182\/blood-2010-07-293977","article-title":"Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure.","volume":"117","author":"Jabbour","year":"2011","journal-title":"Blood"},{"issue":"6","key":"2019111809573930100_B7","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1182\/blood-2006-09-047266","article-title":"Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy.","volume":"109","author":"Hochhaus","year":"2007","journal-title":"Blood"},{"issue":"10","key":"2019111809573930100_B8","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","article-title":"Nilotinib (formerly AMN107), a highly selective Bcr-Abl tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"issue":"35","key":"2019111809573930100_B9","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019111809573930100_B10","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1038\/sj.leu.2402996","article-title":"Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa.","volume":"17","author":"Marin","year":"2003","journal-title":"Leukemia"},{"issue":"9","key":"2019111809573930100_B11","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa011573","article-title":"Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.","volume":"346","author":"Kantarjian","year":"2002","journal-title":"N Engl J Med"},{"issue":"19","key":"2019111809573930100_B12","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1200\/JCO.2007.14.9260","article-title":"Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia.","volume":"26","author":"Shah","year":"2008","journal-title":"J Clin Oncol"},{"issue":"17","key":"2019111809573930100_B13","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1182\/blood-2011-05-355594","article-title":"Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome positive CML patients with resistance or intolerance to imatinib.","volume":"118","author":"Cortes","year":"2011","journal-title":"Blood"},{"issue":"2","key":"2019111809573930100_B14","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1159\/000046635","article-title":"Cytogenetic and molecular monitoring of residual disease in chronic myeloid leukaemia.","volume":"107","author":"Kaeda","year":"2002","journal-title":"Acta Haematol"},{"issue":"4","key":"2019111809573930100_B15","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/sj.leu.2403664","article-title":"Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapse.","volume":"19","author":"Marin","year":"2005","journal-title":"Leukemia"},{"issue":"10","key":"2019111809573930100_B16","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1182\/blood-2005-08-3320","article-title":"Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy.","volume":"107","author":"Kaeda","year":"2006","journal-title":"Blood"},{"issue":"1","key":"2019111809573930100_B17","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"issue":"4","key":"2019111809573930100_B18","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/sj.leu.2404137","article-title":"The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib.","volume":"20","author":"Khorashad","year":"2006","journal-title":"Leukemia"},{"issue":"29","key":"2019111809573930100_B19","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1200\/JCO.2008.16.9953","article-title":"The finding of kinase domain mutations in chronic phase CML patients responding to imatinib may identify those at high risk of disease progression.","volume":"26","author":"Khorashad","year":"2008","journal-title":"J Clin Oncol"},{"issue":"20","key":"2019111809573930100_B20","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","article-title":"Imatinib for newly diagnosed patients with chronic myeloid leukaemia: incidence of sustained responses in an intention-to-treat analysis.","volume":"26","author":"de Lavallade","year":"2008","journal-title":"J Clin Oncol"},{"key":"2019111809573930100_B21","article-title":"Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. [published online ahead of print, November 7, 2011].","author":"Marin","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111809573930100_B22","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1182\/blood.V96.1.86","article-title":"Estimating leukemia-free survival after allografting for chronic myeloid leukemia: a new method that takes into account patients who relapse and are restored to complete remission.","volume":"96","author":"Craddock","year":"2000","journal-title":"Blood"},{"key":"2019111809573930100_B23","doi-asserted-by":"crossref","DOI":"10.1007\/0-387-29150-4","article-title":"Recurrent event survival analysis.","volume-title":"Survival Analysis: A Self-Learning Text","author":"Kleinbaum","year":"2005"},{"key":"2019111809573930100_B24","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk.","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"2019111809573930100_B25","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1214\/aos\/1176350951","article-title":"A class of K-sample tests for comparing the cumulative incidence of a competing risk.","volume":"16","author":"Gray","year":"1988","journal-title":"Ann Stat"},{"key":"2019111809573930100_B26","article-title":"Analisis de eventos recurrentes y de riesgos competitivos. Analisis de la supervivencia y modelo de riesgos proporcionales de Cox.","author":"Domenech","year":"2011"},{"issue":"1","key":"2019111809573930100_B27","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/cncr.26249","article-title":"Expanding Nilotinib Access in Clinical Trials (ENACT).","volume":"118","author":"Nicolini","year":"2012","journal-title":"Cancer"},{"issue":"25","key":"2019111809573930100_B28","doi-asserted-by":"crossref","first-page":"5497","DOI":"10.1182\/blood-2010-06-291922","article-title":"Efficacy of tyrosine kinase inhibitors (TKI) as third line therapy in patients with chronic myeloid leukemia in chronic phase who have failed two prior TKI.","volume":"116","author":"Ibrahim","year":"2010","journal-title":"Blood"},{"issue":"3","key":"2019111809573930100_B29","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1182\/blood-2008-02-141580","article-title":"Failure to achieve a major cytogenetic response by twelve months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia.","volume":"112","author":"Tam","year":"2008","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/8\/1838\/1354871\/zh800812001838.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/8\/1838\/1354871\/zh800812001838.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,28]],"date-time":"2020-06-28T21:19:42Z","timestamp":1593379182000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/119\/8\/1838\/30384\/Responses-to-secondline-tyrosine-kinase-inhibitors"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,23]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2012,2,23]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-10-383000","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,23]]}}}